A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Jin, Yangbing, Zhang, Zehui, Zou, Siyi, Li, Fanlu, Chen, Hao, Peng, Chenghong, Deng, Xiaxing, Wen, Chenlei, Shen, Baiyong, Zhan, Qian
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010262/
https://ncbi.nlm.nih.gov/pubmed/33816276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.634881
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars